Treatment of mild to moderate ulcerative colitis

Tags:

gastrointestinal diseases, colitis

5/5 — (2 votes)

Colitis is one of the most common pathologies of the gastrointestinal tract. It is an inflammatory disease of the large intestine (or rather, its mucous membrane) with pronounced symptoms , which we will talk about later. The disease can be complicated by inflammatory processes in the stomach and small intestine . It often accompanies some other acute and chronic diseases (influenza, pneumonia, typhoid, mumps, malaria, etc.).

It happens that this disease, due to similar symptoms, is confused with irritable bowel syndrome and for this reason is sometimes misdiagnosed. But since irritable bowel syndrome is not associated with the colon, then, accordingly, it cannot have anything in common with colitis.

Colitis

Types of colitis

There are two types of colitis: acute and chronic. The disease usually begins with an acute form with characteristic pain, flatulence and nausea. But prolonged acute colitis can cause the development of a chronic form of the disease.

Chronic colitis is characterized by the presence of pathological changes in the structure of the intestinal mucosa. The cause of these changes is a prolonged inflammatory process, which leads to degeneration of the affected tissues and dysfunction of the large intestine. Often inflammation of the large intestine can cause damage to the small intestine.

Colitis is also divided into several types depending on the causes of the disease:

• infectious colitis is associated with infectious diseases;
• nutritional problems arise due to malnutrition;
• toxic exogenous colitis caused by poisoning with harmful substances;
• endogenous colitis is observed due to intoxication with catabolic products;
• drug colitis develops under the influence of drugs;
• allergic colitis becomes an allergic reaction of the body to pathogens;
• Mechanical colitis is the result of regular mechanical irritation of the intestinal mucosa.

In some cases, inflammation of the large intestine can be caused by several factors. Then doctors diagnose combined colitis.

Therapeutic approaches for widespread ulcerative colitis

From 20% to 40% of patients with ulcerative colitis have X-ray endoscopic signs of disease extending proximally to the left flexure of the colon. This form is classified as total colitis or “pancolitis”. Patients with ulcerative colitis with total damage to the colon have a more aggressive course of the disease with the development of intestinal and extraintestinal complications, a less favorable response to treatment and, therefore, a worse prognosis. This group has the highest surgical activity and mortality. Among patients with total colitis, at least a third will have a chronic continuous course of the disease, when clinical remission is not achieved at all during drug treatment. In addition, if even mild and moderate forms of the disease are not treated prophylactically, then 90% of patients will have repeated exacerbations within a year. Patients with total colitis have an increased risk of developing dysplasia and colon cancer. Thus, the goal of therapy for already widespread colitis will be not only the induction and maintenance of remission, but also the prevention of complications associated with the disease, including malignant neoplasms.

Induction of remission in mild to moderate widespread colitis

Patients with mild to moderate widespread colitis should begin treatment with aminosalicylates. Typically, the first line of therapy is sulfasalazine at a daily dose of 4–6 g/day or mesalazine (Salofalk), to which up to 80% of patients respond by achieving clinical remission or improvement within 4 weeks.

If there is no effect from aminosalicylates within 1–3 weeks or their intolerance, moderate disease activity, they resort to the second line of therapy, namely the use of oral glucocorticoids. Oral prednisolone also shows a dose-dependent effect in the range from 20 mg to 60 mg/day. At the same time, a dose of 60 mg/day is more effective than 40 mg/day, although it is accompanied by an increase in side effects. The maximum dose of prednisolone is maintained until there is clear clinical improvement, and then it is reduced by 5–10 mg weekly to 20 mg/day, then by 2.5 mg per week until complete withdrawal. Prednisolone is taken once in the morning, since there is no increase in the effectiveness of treatment when dividing the daily dose into 2-3 doses. A population-based study examined the outcomes of treatment with systemic corticosteroids immediately after treatment (30 days) and after 1 year [14]. Complete remission after a month of hormonal therapy was observed in 54% of patients, partial in 30%, and no response in 16%. But meta-analyses assessing the effectiveness of current drug therapy for ulcerative colitis show that almost 90% of patients with mild to moderate disease achieve complete clinical remission or partial improvement when treated with glucocorticoids [25, 45]. When prescribing steroids, aminosalicylates are discontinued and the dose of prednisolone is reduced to 20–30 mg per day in order to maintain the clinical and endoscopic effect. Unlike Crohn's disease, hormonal dependence is not common, and therefore, not all patients will need to take immunomodulators. Most patients with ulcerative colitis, after achieving corticosteroid-induced remission, can be maintained with sulfasalazine and mesalazine.

Although existing budesonide formulations are not specifically designed for the treatment of advanced ulcerative colitis, there are studies suggesting the possibility of a favorable outcome in patients in whom systemic steroids are not desirable due to comorbidities. We tested Budenofalk in a small group of patients (21 people) and were convinced of the safety and effectiveness of such therapy. These were elderly patients with hypertension, coronary heart disease, atrial fibrillation, and diabetes mellitus. Budenofalk was prescribed at an initial dose higher than the recommended dose - 15-18 mg/day, but 1-2 weeks after achieving a clinical effect it was reduced to 9 mg/day. The total duration of the course was 8–12 weeks. Treatment was carried out simultaneously with oral aminosalicylates or azathioprine, which were maintained as maintenance therapy.

Treatment of severe and fulminant attacks of ulcerative colitis

Severe or fulminant colitis is considered an “extreme” form of the disease with the threat of life-threatening complications. Such an attack can be a manifestation of ulcerative colitis or occur during the chronic relapsing course of the disease. These patients require hospitalization and vigorous treatment. The intensive management protocol includes colonic rest with total parenteral nutrition, antibiotics, and intravenous corticosteroids.

As a general measure, after hospitalization of the patient, the water and electrolyte balance is restored, the disturbances of which contribute to the development of toxic dilatation. Although the patient may experience intense abdominal pain associated with defecation and frequent, debilitating urges, the use of narcotic analgesics, loperamide and diphenoxylate should be avoided. It is necessary to stop taking medications that the patient was previously receiving, including sulfasalazine and 5-aminosalicylic acid (5-ASA). Due to disturbances in their pharmacokinetics under conditions of accelerated transit, acidic pH and dysbiosis, they will not bring additional effectiveness, but may cause a paradoxical outbreak of activity. Concurrent use of mesalazine or sulfasalazine has, moreover, been associated with loss of response to glucocorticoids. Meeting macro- and micronutrient needs is part of the overall patient management plan. If the patient is able to eat on his own, then it is unlikely that his transfer to enteral or parenteral nutrition is necessary. It is enough to reduce the content of dietary fiber and exclude lactose-containing products if they are intolerant. If there is no other possibility, then total parenteral nutrition is not used to relieve a severe attack, but only to prevent protein-calorie starvation. It is quite difficult to decide the need for antibiotic therapy in febrile patients. Although controlled trials of oral vancomycin, intravenous metronidazole, and ciprofloxacin have not demonstrated therapeutic efficacy, they may be appropriate for septic conditions or ongoing enteric infections. A life-saving measure in the treatment of severe total colitis is the use of corticosteroid hormones. A number of authors suggest oral administration of 60–80 mg prednisolone if there are no problems with gastric emptying, based on the lack of direct clinical comparisons of oral and intravenous administration regimens. However, usually the seriously ill patient is treated intravenously. For this purpose, 100 mg hydrocortisone is administered every 6 hours or 60 mg methylprednisolone is administered once in the morning, which has the advantage of less mineralocorticoid activity and will therefore cause less edema and hypertension. It appears that continuous infusion is preferable to bolus administration. The use of supratherapeutic doses of hormones (methylprednisolone 1 g) used in hematological practice has not proven effective in treating severe attacks of ulcerative colitis. You can expect a decrease in temperature and frequency of bowel movements over several days, and sometimes even overnight. In patients who respond to treatment, the intravenous regimen can be switched to oral therapy after 3 days. In this case, it is necessary to avoid a possible sharp drop in the concentration of steroids in the blood, when, for example, intravenous administration is stopped the evening before, and the oral drug is not used until the morning. Typically, both routes of corticosteroid administration are “crossed” within 12 hours. The rate of reduction in the dose of hormones is regulated depending on the speed of the effect, but, as with moderate forms of ulcerative colitis, the duration of treatment is 10–12 weeks. The use of intravenous glucocorticoids provides a clinical response in 53–81% of patients. A double-blind, randomized trial comparing intravenous hydrocortisone and adrenocorticotropic hormone (ACTH) showed that patients who had previously received steroids responded better to hydrocortisone and those who had not been treated with steroids in the past month responded better to ACTH [26]. Interestingly, there was a positive correlation between the severity of colitis and response to intravenous therapy [27]. Unfortunately, 20–30% of patients with severe colitis will not benefit from intravenous steroids. These patients should be observed in close contact with a surgeon experienced in managing such patients to make a timely decision about surgery. Failure to respond within 7–10 days of intravenous therapy is an indication for cyclosporine or colectomy. It should be noted that cyclosporine monotherapy is also used in cases where a severe attack cannot be treated with intravenous steroids due to intolerance.

Maintaining remission of common ulcerative colitis

Ulcerative colitis is an exacerbating disease that requires two-phase pharmacological therapy: first with induction and then maintenance agents. Aminosalicylates are the most important drugs for achieving both goals. When prescribed, the annual rate of exacerbations is reduced to 30–50% compared to 80% when no maintenance treatment is provided [22]. However, unresolved questions remain: which 5-ASA drugs should be preferred, in what dose and for how long should the patient be treated.

Sulfasalazine maintains remission in 71–88% of patients when given in doses of 1 g to 4 g per day with a dose-dependent effect. A dose of 2 g was chosen as the most balanced between effectiveness and side effects. Mesalazine is a different matter, where high doses are safe. It was found that a dose-dependent effect appears at higher doses - up to 4-5 g/day. This has changed the general approach to choosing the dose of aminosalicylates. If previously, after achieving remission, the dose was reduced, now the standard of treatment has changed. Maintain the same dose of mesalazine for both induction and maintenance of remission. There are also discrepancies regarding the choice of 5-ASA drug. Although a meta-analysis favors sulfasalazine [40], there is no strong evidence that one 5-ASA formula is superior to another in maintenance therapy [35]. Next, the physician and patient must make a choice based on efficacy data, potential side effects, and practical considerations such as compliance and cost. For example, in inducing and maintaining remission of left-sided colitis, rectally administered 5-ASA preparations (suppositories, enemas, Salofalk aerosol) are better than oral ones. But in practice, oral medications (tablets, Salofalk granules) are used more often due to patient preference. The combination of oral and topical 5-ASA drugs demonstrates the greatest preventive effect. In patients with left-sided colitis, exacerbations developed in 64% of cases on maintenance treatment with oral mesalazine and only in 36% receiving a combination of oral mesalazine and 5-ASA enema 4 g 2 times a week [11]. Thus, compliance may be improved by intermittent rectal administration of drugs or by reducing the frequency of oral 5-ASA dosing, for example, twice daily. Recently, a new formula of mesalazine was created based on multi-matrix technology - MMX-mesalazine (the drug is not registered in the Russian Federation), releasing 5-ASA throughout the colon. Its tablet contains 1.2 g of 5-ASA, and the drug is taken once a day, which is convenient for the patient. When comparing MMX-mesalazine at a dose of 2.4 g and 4.8 g of Asakol (the drug is not registered in the Russian Federation), its high effectiveness and tolerability were confirmed [21]. There is always a transition period between inductive glucocorticoid therapy and maintenance treatment with aminosalicylates. In practice, most patients requiring exacerbation with steroids will also require high doses of mesalazine to maintain remission (2.5–5 g/day). Only after a year of stable remission is it possible to attempt to reduce the dose to 1.5–2.0 g. No one can say how long maintenance therapy should be carried out. Most experts recommend doing this constantly and continuously. However, in a patient with a mild episode or infrequent mild exacerbations, observation without long-term drug maintenance may be chosen. A number of randomized trials have attempted to answer this question, with conflicting results. A prospective cohort study found that ulcerative colitis worsened in all newly diagnosed patients within 10 years despite supportive treatment, and this occurred in the first 2–3 years. This suggests that maintenance treatment at an adequate dose should continue for at least 2 years. In other studies, taking 5-ASA reduced the frequency of exacerbations in patients with ulcerative colitis even after 2 years of remission [3]. Since aminosalicylates reduce the risk of cancer, this is another good reason to continue long-term maintenance treatment. As the results of epidemiological studies show, mesalazine in a dose of over 1.2 g reduces the risk of developing colorectal cancer by 30–80% [2, 13], and in a dose of over 2.4 g significantly limits the transformation of mild to high-grade dysplasia and cancer [ 44].

Management of glucocorticoid-resistant and dependent patients

The natural course of ulcerative colitis is determined by episodes of exacerbation of the disease, which are then replaced by periods of remission. Glucocorticoids shorten the duration of active manifestations of the disease, but treatment does not always lead to the desired result. When corticosteroid therapy is ineffective, two unfavorable outcomes are noted: glucocorticoid (GC) resistance and dependence. These patients stand out from the general series of patients with inflammatory bowel diseases, since they require alternative therapy, mainly immunosuppressive or even experimental. GK-resistance and GK-dependence occur with almost the same frequency, approaching 20%. However, Crohn's disease is more likely to be GC-dependent, and refractory disease often develops in severe ulcerative colitis. The definition of refractoriness differs significantly in these diseases and within ulcerative colitis itself, depending on the severity and extent of the lesion. According to the European consensus in Prague in 2004, GC-refractory Crohn's disease is established in patients with active disease, despite taking prednisolone 0.75 mg/kg/day for 4 weeks [38]. In a severe attack of ulcerative colitis, the disease is considered refractory much earlier—after 5–7 days of intravenous glucocorticoid therapy due to the risk of developing life-threatening complications [16]. In distal colitis, there is greater tolerance and the disease is assessed as refractory after 6–8 weeks of combined treatment with oral and topical steroids [42]. Greater unanimity in views on GC addiction. Although the definition is established by expert consensus for Crohn's disease, it can equally apply to ulcerative colitis. Hormone-dependent patients are considered to be those who cannot reduce the dose of prednisolone below 10 mg/day after 3 months of treatment without exacerbation of the disease or in whom an exacerbation occurs within the same 3 months after stopping GC therapy [38]. Assessment of GC refractoriness and dependence should be carried out after excluding specific complications of the disease and careful assessment of 3 important parameters - the adequacy of the steroid dose, duration of treatment, means and purpose of therapy. “Pseudo-refractoriness,” for example, in patients with left-sided colitis can be caused by proximal colostasis - with frequent, scanty stools mixed with blood, and these symptoms are easily eliminated with bulk laxatives. The patient may “underreceive” therapy due to low doses of oral aminosalicylates or refusal to use local treatment. In some severe patients with ulcerative colitis, refractoriness is associated with local or generalized cytomegalovirus infection [17]. Not long ago, the term “chronic active” disease was still used to designate patients who could be both GC-dependent and refractory, intolerant of steroids, or remain active despite taking immunomodulators. Today it is recommended to abandon it in order not to cause confusion in the grouping of patients, which requires more precise definitions.

Cyclosporine and infliximab are used in the treatment of GC-resistant colitis with a high degree of evidence.

Steroid-dependent forms of ulcerative colitis

Hormonal dependence reflects the patient’s inability to reduce the dose of GC below a certain value without reactivating the disease. There are various approaches to treating this condition. First of all, an attempt to replace GC with high doses of aminosalicylates orally and rectally. If it is unsuccessful, various immunomodulatory agents are used: azathioprine, 6-mercaptopurine (6-MP), methotrexate, mycophenolate mofetil, infliximab. Due to the delayed action of many of them, there is a certain transition period when the patient continues to receive corticosteroid hormones according to a gentle regimen. For example, if a patient with ulcerative colitis maintains signs of clinical remission on a dose of hormones of 20 mg/day, then usually within 1–1.5 months he can be switched to intermittent intake of prednisolone 40 mg every other day by transferring 1 tablet every 6–10 days ( 5 mg) from one day to the next. The advantages of the intermittent regimen are associated with the possibility of stopping treatment at once without the risk of adrenal insufficiency. During the period of taking GC according to an intermittent regimen, the accumulated signs of hormonal saturation do not regress, but do not increase. Its use as a bridge therapy to immunomodulators is fully justified, as documented by a placebo-controlled study showing a decrease in the frequency of exacerbations during intermittent administration of prednisolone 40 mg every other day in patients with GC dependence and frequent exacerbations of the disease [31]. In the same way, budesonide can be used as an alternative to traditional hormones in patients with GC dependence. In this case, prednisolone is replaced by budesonide after a short time of simultaneous use of both drugs. Budesonide (Budenofalk) is prescribed at a dose of 9 mg per day, when the dose of prednisolone is 30 mg. After this, systemic steroids are reduced and discontinued within a month, leaving budesonide. The calculated dose of budesonide is 3 mg corresponding to 10 mg of prednisolone. A study was conducted that included 120 patients with Crohn's disease who were unable to reduce the dose of prednisolone without exacerbations after 2 attempts. Patients were randomized to receive placebo or budesonide 6 mg/day. Systemic steroids were tapered until discontinuation. As the results of the study showed, by week 13, exacerbations of the disease while taking budesonide developed in 32% of patients, while in the placebo group they were experienced by 65% ​​[9].

Azathioprine, 6-mercaptopurine. A national survey of advisory members of the British Society of Gastroenterology conducted in 1999 found azathioprine to be the most popular agent for maintaining remission in ulcerative colitis [39]. Interestingly, doctors experienced in treating inflammatory bowel disease use higher maintenance doses over the long term and recommend this treatment for patients with less extensive disease. The protocol for the use of azathioprine and 6-MP involves a single dose of the drugs at a dose of 2.0–2.5 mg/kg/day and 1.5 mg/kg/day, respectively. The expected effect occurs on average after 3 months. A complete blood count is performed weekly during the first month of treatment, then once every 2 weeks for another 2 months, and then once every 2–3 months. In case of moderate or severe leukopenia (<3 × 105/l) or thrombocytopenia (<100 × 109/l), the drug is temporarily discontinued and resumed after normalization at a lower, individually selected dose. If possible, it is recommended to determine the level of tipurine methyltransferase to prevent myelosuppression. Azathioprine effectively maintains remission for up to 4 years in many patients [5]. To date, there is no doubt about the GC sparring effect of azathioprine, which probably decreases over time. While the role of azathioprine in inducing remission of ulcerative colitis is questionable, this drug looks quite convincing as a maintenance treatment. After achieving remission, active use of azathioprine for a year reduced the frequency of exacerbations of ulcerative colitis from 59% to 36% [18]. The same trends were observed in other studies, and additional administration of 5-ASA did not increase the effectiveness of maintenance therapy. Azathioprine retained its protective effect even after many years of use.

Methotrexate. There is no evidence base for the use of methotrexate for induction and maintenance treatment of ulcerative colitis. The fact is that the doses successfully used in the treatment of Crohn's disease (25 mg per week intramuscularly) have never been tested in patients with ulcerative colitis in appropriate studies. There is only one report of the use of methotrexate 25 mg/week intramuscularly in 8 patients with ulcerative colitis refractory to GCs and immunomodulators, which was unsuccessful [15]. The latest retrospective study of oral methotrexate (average dose 19.9 mg/week) demonstrates remission in 42% of patients, with remission maintained in 38% for 6 months [10]. It is possible that the results of methotrexate in ulcerative colitis would have been better if the drug had been evaluated with intramuscular and subcutaneous administration. A small pilot study in patients intolerant or resistant to azathioprine is encouraging [30]. In any case, this backup option should be kept in mind. The protocol for the use of methotrexate is borrowed from the experience of treating Crohn's disease. It involves parenteral administration of methotrexate 25 mg/week until remission is achieved, followed by a dose reduction to 15 mg/week as maintenance therapy [1]. The optimal duration of treatment is not known, but is thought to be 3–4 years. When carrying out methotrexate therapy, it is recommended to immediately prescribe folic acid 1–2 mg/day in order to minimize side effects. Patients are warned about the need to protect themselves from pregnancy; the intake of alcohol, myelo- and hepatotoxic drugs is prohibited. Treatment should be temporarily discontinued for leukopenia (< 3 × 109/L), neutropenia (< 1.0 × 109/L), thrombocytopenia (< 100 × 109/L) and a threefold increase in ALT and resumed with great caution after normalization. You should be especially attentive to patients with an increased risk of hepatotoxicity - alcohol abusers, overweight and diabetes mellitus. There is a point of view that azathioprine is preferable in patients with GC dependence, when doses of prednisolone less than 20 mg/day are required to maintain remission, and methotrexate is preferable in case of an outbreak of ulcerative colitis at higher doses of prednisolone. Its effect is faster than azathioprine - 4-8 weeks.

Infliximab. Infliximab can be successfully used not only to induce remission of GC-refractory ulcerative colitis, but also in the management of hormone-dependent forms of the disease. For this purpose, a three-time infusion of infliximab is used at 0, 2 and 6 weeks, followed by maintenance treatment with a single infusion of 5 mg/kg/day every 8 weeks in combination with azathioprine. The evidence base can be provided by two recent randomized, placebo-controlled studies - ACT 1 and ACT 2 [33, 34, 36]. The ACT 1 study included 164 patients with moderate to severe ulcerative colitis who remained active despite taking GCs and tipurines. Infliximab was administered at a dose of 5 mg/kg/day and 10 mg/kg/day at 0, 2, 6 weeks and then at 8-week intervals. By week 30, clinical response was achieved in 52.1% in the infliximab 5 mg/kg/day group, 50.8% in the 10 mg/kg/day group versus 29.8% in the placebo group (p < 0.001). The ACT 2 study randomized 364 patients with ulcerative colitis refractory to at least one standard treatment (5-ASA, GCs, or thiopurines). By week 30, clinical response was achieved in 47.1% in the infliximab 5 mg/kg/day group, 60% in the 10 mg/kg/day group versus 26% in placebo (p < 0.001). Patients treated with infliximab were twice as likely to achieve remission with endoscopic healing and steroid withdrawal.

For questions regarding literature, please contact the editor.

V. G. Rumyantsev , Doctor of Medical Sciences, Professor of the ON-CLINIC MMC , Moscow

Symptoms of intestinal colitis

With chronic colitis, the patient feels pain in the abdomen, often on the left, but sometimes it is not possible to localize the source of the pain. The pain intensifies after eating and decreases after defecation. A feeling of heaviness in the abdomen, bloating and flatulence are possible. A characteristic symptom of colitis is stool disorder with mucus and blood in the stool. Constipation may be replaced by diarrhea; the patient often feels the “urge” to defecate without excreting feces.

Colitis may also be accompanied by more “general” symptoms that are not directly related to the gastrointestinal tract, such as fever, weakness and joint pain. The patient loses his appetite, which leads to weight loss. If colitis is accompanied by acute inflammatory processes, then all clinical symptoms appear more clearly.

Are there other surgical alternatives?

Today, a method has been adopted in world practice in which a reservoir is created from the small intestine, connected to the anus. Typically, in this case, it is necessary to form a temporary ileostomy, followed by its closure after a few months.

The reservoir, the so-called pouch, functions as a storage device to reduce the frequency of bowel movements. The use of this technique allows one to achieve physiological stool holding. In cases of complications in the form of inflammation of the reservoir, antibiotic therapy can be carried out, sometimes it is necessary to resort to removal and the creation of a permanent ileostomy.

Diagnosis of colitis

Colitis is diagnosed as a result of a whole range of tests. This includes: macro and microscopy of stool, general blood test, contrast irrigoscopy and colonoscopy. These tests make it possible to detect the presence of helminth eggs, inflammation, and also to study the anatomical and functional features of the large intestine and the condition of the colon mucosa. During a colonoscopy, samples are taken for further histological examination. A proctologist also examines the patient; he examines the anus to exclude the possibility of hemorrhoids, paraproctitis and other pathologies.

Intestinal dysfunction can be complicated by inflammation. In addition, colitis may not be the main disease, but accompany the development of a colon tumor. Therefore, doctors take a biopsy of suspicious areas of the intestinal wall to conduct additional tests and exclude the possibility of malignant neoplasms. If enteritis or other diseases are suspected, a number of diagnostic procedures may be prescribed, for example, an ultrasound of the abdominal organs and functional tests to identify markers of inflammation of the liver and pancreas.

Registration for surgery for ulcerative colitis (UC)

Treatment of UC in Moscow in our clinic is carried out in accordance with the latest standards. We try to perform operations while preserving the function of natural bowel movements and, if possible, avoiding subsequent use of hormonal and anti-inflammatory therapy. We have excellent results when performing total coloproctectomy with the formation of a reservoir from the small intestine and its anastomosis to the anus.

Our department was the first in Russia to accumulate significant experience in performing various types of surgery, both open and laparoscopic. After the intervention, the quality of life of our patients improves significantly. Watch an interview with our patient, who kindly agreed to talk about her experience and life before and after the operation.

If you have decided to consult for surgery in our clinic, make an initial appointment with a doctor by phone. You can also use the appointment form located in the lower right corner of the screen.

Treatment of intestinal colitis

Treatment for colitis depends on its type. Chronic colitis during periods of exacerbation is best treated in a hospital proctology department. If the cause of colitis is an infection, then it will be treated in the infectious diseases department.

A proper diet plays an important role in the treatment of colitis; it is also prescribed by a doctor. The patient's diet should not contain foods that can mechanically or chemically irritate the intestines, for example, fermented milk products. The patient will have to take food in pureed form, in small portions and at least 4-5 times a day. You will also have to give up foods that contribute to gas formation, for example, cabbage and legumes.

Lightly dried unsweetened wheat bread, lean meat and fish are allowed. It is better to steam food. As the patient's condition improves, the list of permitted products is increased.

If the nature of the disease was infectious, then the treatment will be a course, medications for antibacterial therapy will be prescribed by the doctor. For any form of colitis, moderate physical activity and physical therapy are useful.

What is the range of possible surgical interventions?

The range of surgical interventions in case of ineffectiveness of drug treatment and diet for nonspecific ulcerative colitis includes several types of operations. In our clinic you can receive high-quality treatment, whatever the causes of UC and its consequences in a particular case. Doctors will choose the most appropriate type of intervention for each patient. One operation is enough to completely eliminate the disease.

Sometimes the doctor will consider removing the colon while preserving the rectum and anus. At the same time, holding the chair is maintained. The disadvantage of this method is that it maintains the risk of developing colitis and cancer in the remaining part of the rectum.

Prevention of colitis

A good preventative measure to prevent the occurrence of colitis is a balanced diet. Proper nutrition will minimize the risk of various gastrointestinal diseases. It is recommended to exclude the consumption of alcohol, spices, canned food, and switch to fractional meals.

People with diagnosed chronic diseases of the large intestine should be under the supervision of specialists and undergo periodic medical examinations. It is better for them to avoid excessive physical activity and stress, not work at night and monitor their sleep patterns.

Even if you have not suffered from colitis before, no one is immune from this disease. Timely diagnosis and proper treatment of the disease are important, so undergo regular preventive examinations and consult a doctor at the first symptoms of colitis. Do not experiment with self-medication; drug abuse can only harm you.

Causes

The causes of colitis can be a violation of the character and diet:

• poor eating habits;
• irregular poor nutrition;
• alcohol abuse;
• eating poor quality food.

Colitis often occurs as complications of gastrointestinal diseases (pancreatitis, chronic gastritis, hepatitis), and they can also result from food poisoning or intestinal infections. Taking various medications often has a negative effect on the intestinal flora; the resulting dysbiosis provokes inflammation in the large intestine. The reasons for the development of colitis include congenital pathologies of human development and functional insufficiency.

Our services

The administration of CELT JSC regularly updates the price list posted on the clinic’s website. However, in order to avoid possible misunderstandings, we ask you to clarify the cost of services by phone: +7

All services

Make an appointment through the application or by calling +7 +7 We work every day:

• Monday—Friday: 8.00—20.00
• Saturday: 8.00–18.00
• Sunday is a day off

The nearest metro and MCC stations to the clinic:

• Highway of Enthusiasts or Perovo
• Partisan
• Enthusiast Highway

Driving directions